Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Develop Drug-Like Molecules to Improve Schizophrenia Treatment

23.09.2011
Researchers at Vanderbilt University have identified chemical compounds that could lead to a major advance in the treatment of schizophrenia.

In a transaction announced this week, Vanderbilt has licensed the compounds to Karuna Pharmaceuticals in Boston, Mass., for further development leading to human testing.

All current anti-psychotic medications act by binding to serotonin and dopamine receptors in the brain to help control hallucinations and delusions, but they provide little relief of other serious symptoms, including social withdrawal and the inability to pay attention or make decisions. As a result, many patients have difficulty holding a job or living independently. In addition, current drugs have serious side effects.

The new Vanderbilt compounds work in a fundamentally different way than existing medications, by inhibiting glycine transporter one (GlyT1), an action that allows for more normal function of brain cells involved in schizophrenia.

“The potential of these new compounds to ameliorate the devastating social and cognitive deficits of schizophrenia, which do not respond to currently available medications, is very exciting,” said National Institute of Mental Health (NIMH) Director Thomas R. Insel, M.D.

The novel compounds were developed by Jeffrey Conn, Ph.D., and Craig Lindsley, Ph.D., co-directors of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), and their colleagues in the VCNDD, part of Vanderbilt University Medical Center.

“We are delighted to have the opportunity to partner with VCNDD to help these drugs realize their full potential, to bring a valuable new treatment to patients and families suffering with this disabling disease,” commented Karuna CEO Edmund Harrigan, Ph.D., former executive vice president of Worldwide Business Development at Pfizer.

Schizophrenia is a chronic disabling mental illness that affects more than 3 million Americans according to the NIMH, and 24 million people worldwide, according to the World Health Organization. The worldwide market for antipsychotic drugs exceeds $20 billion a year.

The Vanderbilt GlyT1 inhibitors were discovered and developed with support from the NIMH, which in 2010 awarded Vanderbilt a five-year, $10 million grant to establish a National Cooperative Drug Discovery and Development Group, targeting new schizophrenia therapies.

The work is now sufficiently far enough along to hand off to Karuna Pharmaceuticals, a Boston- based company focused on developing breakthrough therapies for schizophrenia.

Conn and Lindsley’s colleagues in the Vanderbilt Center For Neuroscience Drug Discovery on the schizophrenia program include Carrie Jones, Ph.D., the center’s director of in vivo pharmacology; Colleen Niswender, Ph.D., director of molecular pharmacology; and J. Scott Daniels, Ph.D., director of drug metabolism and pharmacokinetics.

It can cost over a billion dollars to bring a drug to market. Cuts in health care reimbursement for medications could make it even more difficult for pharmaceutical companies to recoup that investment. Some firms already are downsizing their research operations as patent protection ends for some of their best-selling brand name products.

That’s where academic medical centers can help. Vanderbilt is uniquely positioned to undertake early stage drug discovery, in part because of its strength in clinical pharmacology, its investment in research infrastructure including high-throughput screening, its ability to attract government, foundation and corporate support and its recruitment of top-notch scientists.

“This work shows how publicly funded basic research can foster the identification of novel medication targets and promising candidate compounds that industry can then take forward,” Insel said. “It is a wonderful example of translational research with the potential to change lives.”

Bill Snyder | Newswise Science News
Further information:
http://www.vanderbilt.edu

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>